Top Markets
Coin of the day
Apollomics, Inc. Apollomics, Inc.

Apollomics, Inc.

APLM
Kedudukan dalam Saham #25246
Apollomics, Inc., a biotechnology enterprise established in 2015 and... Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.
Harga Saham
$23.57
Disegerakkan terakhir: 2026-08-20
Modal Pasaran
$51.76M
Perubahan (1 hari)
-0.08%
Perubahan (1 tahun)
289.59%
Negara
US
Perdagangan Apollomics, Inc. (APLM)

Kategori

Pendapatan untuk Apollomics, Inc. (APLM)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Apollomics, Inc., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Apollomics, Inc. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
$5.27B -
US
$1.95B -
NL
$1.61B -
AU
- -
CH
$-3.09B -
US